Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time.
1 - 9 . (canceled)
10 . A biodegradable ocular implant comprising an active agent and a biodegradable polymer, wherein the active agent is a cyclosporine, the biodegradable polymer is a polylactic acid, polyglycolic acid co-polymer, and the implant being formed for subconjunctival insertion.
11 . The biodegradable ocular implant of claim 10 wherein the polylactic acid, polyglycolic acid co-polymer is present in an amount of at least about 20 weight percent of the implant.
12 . The biodegradable ocular implant of claim 10 wherein the cyclosporine is dispersed within the polylactic polyglycolic acid co-polymer.
13 . The biodegradable ocular implant of claim 10 wherein the implant is made by an extrusion method.
14 . The biodegradable ocular implant of claim 10 wherein the implant includes forms selected from the group consisting of sheets, pluralities of particles, fibers, microcapsules, discs, microspheres and filaments.
15 . The biodegradable ocular implant of claim 10 wherein the implant includes forms selected from the group consisting of pluralities of particles and microspheres.
16 . The biodegradable ocular implant of claim 10 wherein the active agent is homogeneously distributed through the biodegradable polymer.
17 . The biodegradable ocular implant of claim 10 wherein the implant is sized or shaped to be compatible with the site of insertion.
18 . The biodegradable ocular implant of claim 10 wherein the implant is dimensioned to be compatible with the size and shape of the site of insertion.
19 . The biodegradable ocular implant of claim 10 wherein the implant is structured to facilitate both subconjunctival insertion and accommodation of the implant.
20 . A biodegradable ocular implant comprising an active cyclosporine and a biodegradable polylactic acid, polyglycolic acid copolymer, the implant being sized and shaped for subconjunctival insertion.
21 . The biodegradable ocular implant of claim 20 wherein the implant is structured to facilitate both subconjunctival insertion and accommodation of the implant.
22 . The biodegradable ocular implant of claim 20 wherein the implant is dimensioned to be compatible with the size and shape of the site of insertion.
23 . The biodegradable ocular implant of claim 20 wherein the polylactic acid, polyglycolic acid co-polymer is present in an amount of at least about 20 weight percent of the implant.
24 . The biodegradable ocular implant of claim 20 wherein the cyclosporine is dispersed within the polylactic polyglycolic acid co-polymer.
25 . The biodegradable ocular implant of claim 20 wherein the implant is made by an extrusion method.
26 . The biodegradable ocular implant of claim 20 wherein the implant includes forms selected from the group consisting of sheets, pluralities of particles, fibers, microcapsules, discs, microspheres and filaments.
27 . The biodegradable ocular implant of claim 20 wherein the implant includes forms selected from the group consisting of pluralities of particles and microspheres.
28 . The biodegradable ocular implant of claim 20 wherein the active agent is homogeneously distributed through the biodegradable polymer.
29 . The biodegradable ocular implant of claim 20 wherein the cyclosporine is present in an amount in a range of at least about 1 weight percent to about 80 weight percent of the implant.